South Asia has achieved its highest-ever immunization coverage for children, with notable progress in India and Nepal, ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

A company was ordered to pay hundreds of thousands of dollars to D.C. to settle claims that it engaged in an illegal kickback scheme.

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out by the World Health Organisation.

South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir, that research ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...